BRPI1010514A2 - derivados de indol e métodos para tratamento antiviral - Google Patents

derivados de indol e métodos para tratamento antiviral

Info

Publication number
BRPI1010514A2
BRPI1010514A2 BRPI1010514A BRPI1010514A BRPI1010514A2 BR PI1010514 A2 BRPI1010514 A2 BR PI1010514A2 BR PI1010514 A BRPI1010514 A BR PI1010514A BR PI1010514 A BRPI1010514 A BR PI1010514A BR PI1010514 A2 BRPI1010514 A2 BR PI1010514A2
Authority
BR
Brazil
Prior art keywords
methods
indole derivatives
antiviral treatment
antiviral
treatment
Prior art date
Application number
BRPI1010514A
Other languages
English (en)
Inventor
A Nomeir Amin
A Turpoff Anthony
Morrill Christie
Li Chunshi
George Njoroge F
Mitchell Karp Gary
Chen Guangming
Ren Hongyu
Takasugi James
Zhu Jin
Maccoss Malcom
Zhang Nanjing
Kakarla Ramesh
Liu Ronggang
W Smith Sean
Xiao Huang Song
D Paget Steven
Joseph Lennox William
Zhang Xiaoyan
Liu Yalei
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of BRPI1010514A2 publication Critical patent/BRPI1010514A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
BRPI1010514A 2009-04-06 2010-04-05 derivados de indol e métodos para tratamento antiviral BRPI1010514A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16689309P 2009-04-06 2009-04-06
PCT/US2010/029923 WO2010117932A1 (en) 2009-04-06 2010-04-05 Indole derivatives and methods for antiviral treatment

Publications (1)

Publication Number Publication Date
BRPI1010514A2 true BRPI1010514A2 (pt) 2019-09-24

Family

ID=42257856

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010514A BRPI1010514A2 (pt) 2009-04-06 2010-04-05 derivados de indol e métodos para tratamento antiviral

Country Status (21)

Country Link
US (1) US8735414B2 (pt)
EP (1) EP2417122A1 (pt)
JP (1) JP2012522806A (pt)
KR (1) KR20120007026A (pt)
CN (1) CN102695704A (pt)
AR (1) AR076265A1 (pt)
AU (1) AU2010234650A1 (pt)
BR (1) BRPI1010514A2 (pt)
CA (1) CA2757640A1 (pt)
CO (1) CO6450616A2 (pt)
CR (1) CR20110542A (pt)
EC (1) ECSP11011434A (pt)
IL (1) IL215559A0 (pt)
MX (1) MX2011010482A (pt)
NI (1) NI201100178A (pt)
NZ (1) NZ596144A (pt)
RU (1) RU2011144819A (pt)
SG (2) SG175048A1 (pt)
TW (1) TWI427076B (pt)
WO (1) WO2010117932A1 (pt)
ZA (1) ZA201108107B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5965484B2 (ja) 2012-07-27 2016-08-03 佐藤製薬株式会社 ジフルオロメチレン化合物
CA3036776A1 (en) 2016-09-16 2018-03-22 Sumitomo Chemical Company, Limited Heterocyclic compound, and harmful-arthropod-controlling agent containing same
WO2018213365A1 (en) * 2017-05-15 2018-11-22 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
CN113135900B (zh) * 2021-03-12 2022-05-24 中山大学 吲哚嘧啶类化合物及其合成方法和应用
CN112891343B (zh) * 2021-03-22 2022-04-01 华中农业大学 3-吲哚乙腈在制备抑制新型冠状病毒SARS-CoV-2药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103147T1 (tr) * 1999-12-27 2002-06-21 Japan Tobacco Inc. Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı.
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AU2004251175A1 (en) * 2003-06-05 2005-01-06 Merck & Co., Inc. Substituted indoles and a process for preparing substituted indoles
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008506702A (ja) * 2004-07-14 2008-03-06 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎を治療するための方法
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
WO2007027454A1 (en) * 2005-08-30 2007-03-08 Bristol-Myers Squibb Company Heterocyclic dihydropyrimidine compounds
WO2008009079A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
CL2008001257A1 (es) * 2007-05-04 2008-07-04 Wyeth Corp Compuestos triciclicos, inhibidores de metaloproteinasas matriciales; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, osteoartritis, aterosclerosis, cancer de pulmon, entre otras.
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2010041983A1 (ru) * 2008-10-06 2010-04-15 Алла Хем, Ллс Замещенные 3-арилсульфoнил-пиpaзoлo[1,5-a]пиpимидины, антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения

Also Published As

Publication number Publication date
US8735414B2 (en) 2014-05-27
KR20120007026A (ko) 2012-01-19
US20120184574A1 (en) 2012-07-19
JP2012522806A (ja) 2012-09-27
CR20110542A (es) 2012-01-30
RU2011144819A (ru) 2013-05-20
AU2010234650A1 (en) 2011-11-03
ZA201108107B (en) 2013-01-30
NZ596144A (en) 2014-01-31
TW201103900A (en) 2011-02-01
ECSP11011434A (es) 2011-12-30
TWI427076B (zh) 2014-02-21
AR076265A1 (es) 2011-06-01
CO6450616A2 (es) 2012-05-31
CN102695704A (zh) 2012-09-26
SG175047A1 (en) 2011-11-28
NI201100178A (es) 2012-01-23
MX2011010482A (es) 2012-01-30
IL215559A0 (en) 2011-12-29
EP2417122A1 (en) 2012-02-15
WO2010117932A1 (en) 2010-10-14
CA2757640A1 (en) 2010-10-14
SG175048A1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
ES2643164T3 (es) Indol 7-sustituido como inhibidores de Mcl-1
BRPI1008749A2 (pt) Derivados de benzodiazepina
DOP2012000282A (es) Indoles sustituidos como inhibidores ezh2
BRPI0906436A2 (pt) Derivados de ftalazinona
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BR112012006630A2 (pt) derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)
GB0905328D0 (en) Indole derivatives
ZA201104361B (en) Substituted dioxopiperidinyl phthalimide derivatives
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI1013844A2 (pt) derivados de piridina-isoxazol
DK2397480T3 (da) Diazepindionderivat
HK1149762A1 (en) Substituted indole derivatives
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
DK2361116T3 (da) Bestrålingsindretning
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BRPI0809221A2 (pt) indol carboxamidas como inibidores de ikk2
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
BRPI1011416A2 (pt) derivados de antraquinova novos
BRPI1010514A2 (pt) derivados de indol e métodos para tratamento antiviral
GB0909441D0 (en) Novel indole derivatives
ZA200905265B (en) Indole derivatives
BRPI1008855A2 (pt) derivados de indol como agentes anticâncer
BR112012001680A2 (pt) Derivados de tazaroteno

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.